Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer—A Study of the GANNET53 Consortium

Background: Stabilized mutant p53 protein (mutp53) is a novel target in epithelial ovarian cancer. Due to aberrant conformation, mutp53 proteins depend on folding support by the Hsp90 chaperone. Hsp90 blockade induces degradation of mutp53, resulting in tumor cell cytotoxicity and increased sensitiv...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Oncol
Hlavní autoři: Ray-Coquard, Isabelle, Braicu, Ioana, Berger, Regina, Mahner, Sven, Sehouli, Jalid, Pujade-Lauraine, Eric, Cassier, Philippe Alexandre, Moll, Ute Martha, Ulmer, Hanno, Leunen, Karin, Zeimet, Alain Gustave, Marth, Christian, Vergote, Ignace, Concin, Nicole
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2019
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6746955/
https://ncbi.nlm.nih.gov/pubmed/31552170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00832
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky